超声引导肝细胞癌射频消融术后局部肿瘤进展的危险因素分析

摘要/Abstract

摘要： 目的研究超声引导肝细胞癌(HCC)射频消融术后影响局部肿瘤进展的危险因素。方法对99例患者107个病灶行超声引导经皮射频消融治疗,所有患者均进行超声造影血流灌注、肝组织硬度等检查,平均随访时间10.6个月。采用单因素分析和Cox多因素分析方法,研究HCC患者射频消融治疗后局部肿瘤进展的危险因素。结果肿瘤大小、是否邻近较大血管、血流灌注程度和肝组织硬度是HCC射频消融治疗后局部肿瘤进展独立危险因素,其风险比分别为1.12、1.38、1.59和1.77;HCC射频消融前行肝动脉化疗栓塞是局部肿瘤进展的保护因素,风险比为0.52。结论肿瘤大小、是否邻近较大血管、肿瘤血流灌注程度和肝组织硬度是HCC射频消融后局部肿瘤进展的独立影响因素,射频消融前行肝动脉化疗栓塞可有效降低局部肿瘤进展发生率。

关键词: 肝细胞癌, 射频消融, 超声, 局部肿瘤进展

Abstract: Objective To investigate the risk factors for local tumor progression (LTP) after ultrasound-guided radiofrequency ablation (RFA) in treatment of hepatocellular carcinoma (HCC).Methods Ninety-nine patients with 107 lesions involved in this study received RFA for HCC. Contrast-enhanced ultrasound (CEUS) perfusion parameters, liver stiffness measurement (LSM) and other examinations in all those patients were collected at a mean follow-up of 10.6 months. Kaplan-Meier model, log-rank test and Cox proportional hazard model was applied for survival analysis and identifying risk factors for LTP in HCC patients after RFA.Results Tumor size, distance to large vessels, tumor perfusion and LSM were independent risk factors for LTP with the hazard ratios (HR) as 1.12, 1.38, 1.59 and 1.77, respectively. Additionally, transarterial chemoembolization (TACE) before RFA treatment was a protective factor for LTP (HR 0.52).Conclusion Tumor size, distance to large vessels, tumor perfusion and LSM are the most important risk factors for LTP after RFA. Besides, using TACE before RFA treatment can effectively improve LTP.

Key words: Hepatocellular carcinoma, Radiofrequency ablation, Ultrasound, Local tumor progression

李猛, 李志艳, 皋月娟, 张大鹍, 董景辉, 汤雨, 田江克. 超声引导肝细胞癌射频消融术后局部肿瘤进展的危险因素分析[J]. 肝脏, 2017, 22(2): 104-107.

LI Meng LI Zhi-yan GAO Yue-juan ZHANG Da-kun DONG Jing-hui TANG Yu TIAN Jiang-ke. Local tumor progression after ultrasound-guided radiofrequency ablation for hepatocellular carcinoma: risk factors analysis[J]. Chinese Hepatolgy, 2017, 22(2): 104-107.

参考文献

[1] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379:1245-1255.
[2] Ayav A, Germain A, Marchal F, et al. Radiofrequency ablation of unresetable liver tumors: factors associated with imcomplete ablation or local recurrence. Am J Surg. 2010, 200:435-439.
[3] Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology, 2011, 53:885-894.
[4] Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology, 2005, 235:728-739.
[5] 韩浩, 陈敏华, 杨薇, 等. 肝细胞癌射频消融后局部肿瘤进展多因素分析. 中华超声影像学杂志. 2012, 21:128-132.
[6] Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol, 2003, 38:200-207.
[7] Azuma S, Asahina Y, Nishimura-Sakurai Y, et al. Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma. Hepatol Res, 2016, 46:312-319.
[8] 侯毅斌, 陈敏华, 严昆, 等. 经皮阻断肝癌血供对提高射频消融疗效的可行性. 中国医学科学院学报, 2008, 30:448-454.
[9] Park MH, Cho JS, Shin BS, et al. Comparison of internally cooled wet electrode and hepatic vascular inflow occlusion method for hepatic radiofrequency ablation. Gut Liver, 2012, 6:471-475.
[10] Seo JY, Kim W, Kwon JH, et al. Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation. Liver Int, 2013, 33:884-893.
[11] Lezzi R, Pompili M, Posa A, et al. Combined locoregional treatment of patients with hepatocellular carcinoma: state of the art. World J Gastroenterol, 2016, 22:1935-1942.
[12] Sun HC, Zhang W, Qin LX, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol, 2007, 47:684-690.
[13] Li D, Kang J, Golas BJ, et al. Minimally invasive local therapies for liver cancer. Cancer Biol Med, 2014, 11:217-236.
[14] Chen MH, Yang W, Yan K, et al. Radiofrequency ablation of problematically located hepatocellular carcinoma: tailored approach. Abdom Imaging. 2008, 33:428-436.
[15] Lin JW, Lin CC, Chen WT, et al. Combining radiofrequency ablation and ethanol injection may achieve comparable long-term outcomes in larger hepatocellular carcinoma (3.1-4cm) and in high-risk locations. Kaohsiung J Med Sci, 2014, 30:396-401.
[16] Chan AK, Hegarty C, Klass D, et al. The role of contrast-enhanced ultrasound in guiding radiofrequency ablation of hepatocellular carcinoma: a retrospective study. Can Assoc Radiol J, 2015, 66:171-178.
[17] Toshikuni N, Takuma Y, Tomokuni J, et al. Planning sonography using real-time virtual sonography and contrast-enhanced sonography for radiofrequency ablation of inconspicuous hepatocellular carcinoma nodules. Hepatogastroenterology, 2015, 62:661-666.